+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Desmoid Tumors - Pipeline Insight, 2021

  • ID: 5237641
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • 180 Life Sciences
  • AFT Pharma
  • Cellestia Biotech
  • Intas Pharmaceuticals
  • Iterion Therapeutics
  • Jina pharmaceuticals
  • MORE
This “Desmoid Tumors - Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Desmoid Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Desmoid Tumors Understanding

Desmoid Tumors: Overview

Desmoid tumors is an abnormal growth that arises from connective tissue. “Desmoid" comes from the Greek word desmos, which means tendon or band-like. These are also known as aggressive fibromatosis or desmoid-type fibromatosis. Desmoid tumors often appear as infiltrative, usually well-differentiated, firm overgrowths of fibrous tissue, and they are locally aggressive. Desmoid tumors can occur in any part of body but most often occur in the abdomen, arms and legs. These are generally not considered cancerous (malignant) because they do not spread to other parts of the body (metastasize); however, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. Desmoid tumors occur frequently in people with an inherited form of colon cancer called familial adenomatous polyposis.

Symptoms

The symptoms of Desmoid Tumors include:
  • A mass or area of swelling
  • Pain
  • Loss of function in the affected area
  • Pain and obstruction of the bowels
  • Cramping and nausea, when desmoid tumors occur in the abdomen
Diagnosis

A diagnosis of Desmoid Tumors is based upon a thorough physical examination and specialized tests. Test like imaging tests, such as CT and MRI are done. Biopsy is done to make a definitive diagnosis. Antibodies are often examined in desmoid tumors, including smooth muscle actin, desmin and KIT, to aid in distinguishing them from other tumors.

Treatment

Some desmoid tumors are slow growing and don't require immediate treatment. Others that grow quickly are treated with surgery, radiation therapy, chemotherapy including anticancer drugs, cryoablation or through combinatorial therapy. Anti-inflammatory drugs may cause the tumor to slowly shrink. Chemotherapy agents used to inhibit growth include Doxorubicin (Adriamycin, Rubex), Dacarabazine (DTIC-Dome) and Carboplatin (Paraplatin). Gleevec and Sorafenib are the two kinase inhibitors that are useful in treating desmoid tumors.

Desmoid Tumors Emerging Drugs Chapters

This segment of the Desmoid Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Desmoid Tumors Emerging Drugs

Nirogacestat: SpringWorks Therapeutics

Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor. It is currently in Phase 3 clinical development for patients with desmoid tumors. The U. S. FDA has granted nirogacestat Orphan Drug Designation for the treatment of desmoid tumors and Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Tegavivint: Iterion Therapeutics

Tegavivint is a potent and selective inhibitor of nuclear β-catenin that binds to TBL1 (Transducin βeta-like Protein One). This enables specific silencing of Wnt-pathway oncogenic gene expression without affecting other necessary cellular functions and thus avoids toxicity issues common to other drugs in this pathway. Tegavivint is currently in Phase 2a clinical trial in progressive desmoid tumors after establishing safety and initial clinical efficacy in Phase 1 study.

Desmoid Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Desmoid Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Desmoid Tumors

There are approx. 12+ key companies which are developing the therapies for Desmoid Tumors. The companies which have their Desmoid Tumors drug candidates in the most advanced stage, i. e. phase III include, SpringWorks Therapeutics.

Phases

This report covers around 12+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Desmoid Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Desmoid Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Desmoid Tumors drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Desmoid Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Desmoid Tumors.
Desmoid Tumors Report Insights
  • Desmoid Tumors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Desmoid Tumors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Desmoid Tumors drugs?
  • How many Desmoid Tumors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Desmoid Tumors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Desmoid Tumors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Desmoid Tumors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • SpringWorks Therapeutics
  • Iterion Therapeutics
  • Cellestia Biotech
  • BioSpecifics Technologies Corp.
  • 180 Life Sciences
  • AFT Pharma
  • Timber Pharmaceuticals
  • MedPacto
  • Intas Pharmaceuticals
  • Jina pharmaceuticals
Key Products
  • Nirogacestat
  • Tegavivint
  • CB-103
  • Collagenase injection
  • Adalimumab
  • Sirolimus topical
  • Vactosertib
  • Endoxifen

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 180 Life Sciences
  • AFT Pharma
  • Cellestia Biotech
  • Intas Pharmaceuticals
  • Iterion Therapeutics
  • Jina pharmaceuticals
  • MORE
Introduction

Executive Summary

Desmoid Tumors: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Desmoid Tumors - Analytical Perspective

In-depth Commercial Assessment
  • Desmoid Tumors companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Desmoid Tumors Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Nirogacestat: SpringWorks Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Tegavivint: Iterion Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Endoxifen: Intas Pharmaceuticals/Jina pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
Collagenase injection: BioSpecifics Technologies Corp.
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Desmoid Tumors Key Companies

Desmoid Tumors Key Products

Desmoid Tumors- Unmet Needs

Desmoid Tumors- Market Drivers and Barriers

Desmoid Tumors- Future Perspectives and Conclusion

Desmoid Tumors Analyst Views

Desmoid Tumors Key Companies

Appendix

List of Tables
Table 1 Total Products for Desmoid Tumors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Desmoid Tumors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • SpringWorks Therapeutics
  • Iterion Therapeutics
  • Cellestia Biotech
  • BioSpecifics Technologies Corp.
  • 180 Life Sciences
  • AFT Pharma
  • Timber Pharmaceuticals
  • MedPacto
  • Intas Pharmaceuticals
  • Jina pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll